Tieton Capital Management LLC trimmed its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) by 24.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 91,948 shares of the company’s stock after selling 30,450 shares during the period. Myriad Genetics accounts for about 3.4% of Tieton Capital Management LLC’s holdings, making the stock its 16th biggest holding. Tieton Capital Management LLC’s holdings in Myriad Genetics were worth $4,230,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of MYGN. BlackRock Inc. raised its position in shares of Myriad Genetics by 6.7% in the second quarter. BlackRock Inc. now owns 11,083,521 shares of the company’s stock valued at $414,192,000 after buying an additional 691,243 shares during the last quarter. Mesirow Financial Investment Management Equity Management acquired a new stake in shares of Myriad Genetics in the second quarter valued at about $14,926,000. Frontier Capital Management Co. LLC raised its position in shares of Myriad Genetics by 18.0% in the second quarter. Frontier Capital Management Co. LLC now owns 2,376,935 shares of the company’s stock valued at $88,826,000 after buying an additional 362,821 shares during the last quarter. Millennium Management LLC raised its position in shares of Myriad Genetics by 771.2% in the second quarter. Millennium Management LLC now owns 329,754 shares of the company’s stock valued at $12,323,000 after buying an additional 291,902 shares during the last quarter. Finally, Prudential Financial Inc. raised its position in shares of Myriad Genetics by 70.3% in the third quarter. Prudential Financial Inc. now owns 606,490 shares of the company’s stock valued at $27,899,000 after buying an additional 250,387 shares during the last quarter. Institutional investors and hedge funds own 98.21% of the company’s stock.

Several research firms recently issued reports on MYGN. Barclays raised their price objective on shares of Myriad Genetics from $35.00 to $38.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 22nd. Zacks Investment Research cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Monday, October 29th. Piper Jaffray Companies upgraded shares of Myriad Genetics from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $38.00 to $53.00 in a research report on Wednesday, October 10th. Deutsche Bank raised their price objective on shares of Myriad Genetics from $37.00 to $43.00 and gave the stock a “hold” rating in a research report on Monday, November 5th. Finally, TheStreet cut shares of Myriad Genetics from a “b” rating to a “c” rating in a research report on Thursday, November 8th. Four equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. Myriad Genetics currently has an average rating of “Hold” and a consensus target price of $41.90.

Myriad Genetics stock opened at $32.66 on Tuesday. Myriad Genetics, Inc. has a 12-month low of $27.27 and a 12-month high of $50.44. The stock has a market cap of $2.35 billion, a P/E ratio of 27.21, a PEG ratio of 1.82 and a beta of 0.51. The company has a quick ratio of 2.83, a current ratio of 3.17 and a debt-to-equity ratio of 0.23.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings data on Tuesday, November 6th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.30 by $0.13. Myriad Genetics had a net margin of 7.07% and a return on equity of 10.07%. The firm had revenue of $202.30 million during the quarter, compared to analysts’ expectations of $203.20 million. During the same period last year, the business earned $0.26 earnings per share. Myriad Genetics’s revenue was up 13.1% compared to the same quarter last year. As a group, equities research analysts predict that Myriad Genetics, Inc. will post 1.5 earnings per share for the current year.

WARNING: “Tieton Capital Management LLC Sells 30,450 Shares of Myriad Genetics, Inc. (MYGN)” was published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2018/11/20/tieton-capital-management-llc-sells-30450-shares-of-myriad-genetics-inc-mygn.html.

Myriad Genetics Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Featured Story: How Investors Use a Balance Sheet

Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.